VTVT — vTv Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1641489 ·
Last close
$17.29
Market Cap
$69.36M
52W High
$44.00
52W Low
$16.71
ADV30
22,897
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -12,426,000 -11,620,000 78,607,000 77,164,000 8,922,000
Jun 2026 0 — -13,930,000 -13,054,000 87,593,000 86,643,000 8,961,000
Mar 2026 36,839,000 — 23,263,000 24,134,000 98,813,000 98,086,000 8,854,000
Dec 2025 0 — -7,885,000 -7,138,000 89,899,000 88,932,000 25,462,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-16,762,000
Investing CF
—
Financing CF
$77,441,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.06
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-315,612,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-8,144,000
Pretax Income TTM
$-6,403,000
Interest Exp TTM
$6,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$36,839,000
EBITDA
$-9,245,000
Free Cash Flow
$674,375
Enterprise Value
$183,466,768
Total Cash
$86,643,000
Total Debt
$0
Shares Out
4,011,465
Trailing EPS
$-0.44
Book Value
$5.19
ROE
-15.8%
ROA
-10.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -32,808,000 -26,974,000 89,899,000 25,462,000 64,437,000 -25,255,000
Dec 2024 1,017,000 -24,180,000 -18,462,000 38,266,000 23,965,000 12,199,000 -25,307,000
Dec 2023 0 -25,502,000 -20,250,000 11,018,000 29,567,000 -24,680,000 -19,081,000
Dec 2022 2,018,000 -22,540,000 -19,164,000 33,238,000 27,399,000 -10,740,000 -16,022,000

TTM Snapshot

Revenues TTM
$36,839,000
NetIncome TTM
$-4,756,000
OpCashFlow TTM
—
Assets (Latest)
$87,593,000
Forward EPS
$-4.34

Peers — same industry

TickerNameMarket CapLastDaily %
MNOV MEDICINOVA INC $68.65M $1.34 —
CING Cingulate Inc. $68.64M $4.72 —
COYA Coya Therapeutics, Inc. $70.84M $3.02 —
GOSS Gossamer Bio, Inc. $67.52M $11.04 —
ZYBT Zhengye Biotechnology Holding Ltd $72.03M $1.52 —

News headlines (Yahoo Finance, 1h cache)

VTv Therapeutics: Q3 Earnings Snapshot
2026-11-05 21:33 · Yahoo
vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 21:01 · Yahoo
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Syste
2026-10-27 12:00 · Yahoo
vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia
2026-10-21 00:02 · Yahoo
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
2026-10-15 07:30 · Yahoo
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
2026-10-10 12:00 · Yahoo
vTv Therapeutics stock jumps on FDA orphan drug status
2026-10-08 13:43 · Yahoo
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
2026-10-07 20:01 · Yahoo
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
2026-10-06 12:00 · Yahoo
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
2026-10-05 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.